

Chiral Bisphosphine Ligands based on Quinoline Oligoamide Foldamer:
Application in Asymmetric Hydrogenation

Lu Zheng, Dan Zheng, Yanru Wang, Chengyuan Yu, Kun Zhang* and Hua Jiang*

Table of contents

1. General Procedures and Materials	2
2. Synthesis of ligands L1-L6	3
3. ^1H NMR, ^{31}P NMR, MS and CD spectra for L[Rh] complexes	17
4. General procedure for the hydrogenation reaction	26
5. Crystal data	53
6. ^1H NMR, ^{31}P NMR and ^{13}C NMR spectra of new compounds	54
7. References.....	76


1. General Procedures and Materials.

All starting compounds and solvents were obtained from commercial suppliers and used as received unless otherwise indicated. Per-deuterated solvents for NMR spectroscopy were obtained from Cambridge Isotope Laboratories. Anhydrous dichloromethane (DCM) and toluene were dried by the solvent purification system. Compounds **1a-1g**,¹ **2a-2d**²⁻⁴, **3**⁵, **5**⁶ were prepared according to the literatures and the NMR spectra of these compounds and the hydrogenation products of **1a-1g** are consistent with the literatures. Column chromatography was carried out on flash grade silica gel, using 0-20 psig pressure. Analytical TLC was carried out using tapered silica plates with a preadsorbent zone


NMR spectra were obtained with JEOL Delta (600 MHz) using chloroform-*d* (CDCl₃) or DMSO-*d*₆ as the solvent. The chemical shift references were as follows: ¹H NMR: chloroform-*d*, 7.26 ppm; DMSO-*d*₆, 2.50 ppm; ¹³C NMR: chloroform-*d*, 77.20 ppm; DMSO-*d*₆, 39.52 ppm. High-resolution mass spectra were recorded on Thermo Exactive or SCIEX TripleTOF 5600⁺ System.

2. Synthesis of ligands L1-L6

Scheme S1. Synthesis of L1-L6.




Conditions: (a) 1-chloro-N,N,2-trimethylprop-1-en-1-amine or oxalyl chloride (2.0 equiv.), compound 1 (0.90 equiv.), DIPEA (3 equiv.), DCM; (b) TFA, DCM, room temperature; (c) H₂PPh₂ (1.1 equiv.), Pd(PPh₃)₄ (10%), TEA (2.0 equiv.), toluene, 80 °C; (d) NaOH (3.0 equiv.), THF/MeOH/H₂O, 40 °C; (e) Pd/C (10%), H₂, EA, room temperature; (f) NaOH (3 equiv.), dioxane.




Compound 4a: Compound 2 (135 mg, 0.22 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution 1-chloro-N,N,2-trimethylprop-1-en-1-amine (60 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus 1-chloro-N,N,2-trimethylprop-1-en-1-amine were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 h and resolved in dry DCM. To the solution of compound 1a (56 mg, 0.20 mmol, 0.90

equiv.) in DCM was slowly added DIPEA (0.12 mL, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 h. The solution was removed and the residue was applied to a quick flash column chromatography to get product as a yellow solid. The solid was dissolved in DCM and TFA was added and the resulting mixture was stirred for another 1 h, and then the solvent and the excess TFA was removed under reduced pressure. The residue was purified by silica gel chromatography to gain compound **4a** as a yellow solid (99 mg, 65% yield). ¹H NMR (600 MHz, CDCl₃) δ 12.60 (s, 1H), 9.11 (d, *J* = 7.2 Hz, 1H), 7.99 (d, *J* = 8.3 Hz, 1H), 7.76 (s, 1H), 7.73 – 7.67 (m, 2H), 7.51 (t, *J* = 8.0 Hz, 2H), 7.42 – 7.31 (m, 14H), 6.74 (d, *J* = 7.1 Hz, 1H), 5.04 (br, 2H), 4.09 (t, *J* = 6.7 Hz, 4H), 2.31 (dp, *J* = 15.2, 8.6, 7.6 Hz, 2H), 1.16 (dd, *J* = 13.2, 6.7 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃) δ 163.8, 163.4, 163.3, 151.5, 151.4, 148.3, 146.3, 144.8, 139.8, 137.4, 136.7, 136.6, 135.6, 134.1, 133.9, 132.0, 131.8, 123.0, 129.9, 129.3, 129.0, 128.9, 128.3, 126.9, 126.7, 123.2, 122.6, 117.7, 115.9, 110.7, 109.5, 101.9, 98.5, 75.5, 75.2, 29.9, 28.4, 28.4. ³¹P NMR (243 MHz, CDCl₃) δ -4.42. HRMS (ESI) calculated for C₄₆H₄₄N₄O₅P [M + H]⁺: 763.3044, found 763.3024.




Compound **4b**: Compound **2** (171 mg, 0.28 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution 1-chloro-N,N,2-trimethylprop-1-en-1-amine (74 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus 1-chloro-N,N,2-trimethylprop-1-en-1-amine were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 h and resolved in dry DCM. To the solution of compound **1b** (58 mg, 0.26 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (0.15 mL, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 h. The solution was removed and the residue was applied to

a quick flash column chromatography to get product as a yellow solid. The solid was dissolved in DCM and TFA was added and the resulting mixture was stirred for another 1 h, and then the solvent and the excess TFA was removed under reduced pressure. The residue was purified by silica gel chromatography to gain compound **4a** as a yellow solid (110 mg, 56% yield). ¹H NMR (600 MHz, CDCl₃) δ 11.96 (s, 1H), 9.83 (s, 1H), 8.94 (d, *J* = 7.3 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 1H), 7.72 (dd, *J* = 18.3, 12.9 Hz, 4H), 7.58 (d, *J* = 7.9 Hz, 2H), 7.35 – 7.20 (m, 12H), 7.10 (t, *J* = 7.1 Hz, 1H), 6.65 (d, *J* = 7.2 Hz, 1H), 4.07 (d, *J* = 5.9 Hz, 4H), 2.28 (q, *J* = 10.3, 7.8 Hz, 2H), 1.14 (d, *J* = 6.7 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃) δ 164.0, 163.6, 163.3, 163.2, 150.3, 148.6, 142.3, 138.5, 138.2, 138.0, 137.9, 137.5, 136.7, 136.6, 134.0, 133.9, 130.4, 130.3, 129.1, 128.8, 128.7, 128.2, 127.5, 126.5, 126.4, 122.8, 122.2, 122.1, 118.4, 116.5, 112.6, 111.4, 99.6, 98.5, 75.5, 75.1, 29.9, 28.3, 19.4. ³¹P NMR (243 MHz, CDCl₃) δ -4.14. HRMS (ESI) calculated for C₄₆H₄₅N₅O₄P [M + H]⁺: 762.3209, found 762.3206.




Compound **4c**: Compound **2** (145 mg, 0.24 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution 1-chloro-N,N,2-trimethylprop-1-en-1-amine (64 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus 1-chloro-N,N,2-trimethylprop-1-en-1-amine were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 h and resolved in dry DCM. To the solution of compound **1c** (60 mg, 0.22 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (0.13 mL, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 h. The solution was removed and the residue was applied to a quick flash column chromatography to get product as a yellow solid. The solid was dissolved in DCM and TFA was added and the resulting mixture was stirred for another

1 h, and then the solvent and the excess TFA was removed under reduced pressure. The residue was purified by silica gel chromatography to gain compound **4a** as a yellow solid (18 mg, 15% yield). ¹H NMR (600 MHz, CDCl₃) δ 12.16 (s, 1H), 10.60 (d, *J* = 6.3 Hz, 1H), 9.09 (d, *J* = 7.5 Hz, 1H), 8.22 (br, 1H), 8.00 (d, *J* = 8.2 Hz, 1H), 7.76 (s, 1H), 7.67 (t, *J* = 8.0 Hz, 1H), 7.62 (d, *J* = 10.1 Hz, 2H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.34 (d, *J* = 7.8 Hz, 1H), 7.18 (t, *J* = 7.5 Hz, 2H), 7.06 (t, *J* = 7.3 Hz, 2H), 6.95 (t, *J* = 7.2 Hz, 5H), 6.82 (br, 1H), 6.75 (t, *J* = 7.4 Hz, 4H), 6.60 (d, *J* = 7.1 Hz, 1H), 4.09 (dd, *J* = 15.9, 6.3 Hz, 4H), 3.85 (s, 2H), 2.30 (dq, *J* = 14.5, 7.5, 6.9 Hz, 2H), 1.19 – 1.11 (m, 12H). ¹³C NMR (150 MHz, CHLOROFORM-D CDCl₃) δ 167.8, 150.1, 138.7, 133.7, 133.6, 133.5, 132.4, 131.0, 130.0, 128.9, 128.8, 128.4, 128.3, 128.1, 127.9, 125.5, 123.2, 122.7, 122.4, 99.3, 98.7, 75.4, 75.2, 65.7, 30.7, 29.8, 28.3, 27.3, 22.8 19.3, 19.2. ³¹P NMR (243 MHz, CDCl₃) δ -19.32. HRMS (ESI) calculated for C₄₆H₄₅N₅O₄P [M + H]⁺: 762.3203, found 763.3201.




Compound 4d: Compound **2** (145 mg, 0.24 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution 1-chloro-N,N,2-trimethylprop-1-en-1-amine (64 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus 1-chloro-N,N,2-trimethylprop-1-en-1-amine were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 h and resolved in dry DCM. To the solution of compound **1d** (60 mg, 0.22 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (0.13 mL, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 h. The solution was removed and the residue was applied to a quick flash column chromatography to get product as a yellow solid. The solid was

dissolved in DCM and TFA was added and the resulting mixture was stirred for another 1 h, and then the solvent and the excess TFA was removed under reduced pressure. The residue was purified by silica gel chromatography to gain compound **4a** as a yellow solid (80 mg, 53% yield). ¹H NMR (600 MHz, CDCl₃) δ 11.99 (s, 1H), 10.14 (s, 1H), 8.91 (d, *J* = 7.6 Hz, 1H), 8.02 (d, *J* = 8.3 Hz, 1H), 7.78 (s, 1H), 7.72 (s, 1H), 7.70 – 7.61 (m, 4H), 7.40 (dd, *J* = 15.3, 7.6 Hz, 1H), 7.32 – 7.27 (m, 3H), 6.67 (d, *J* = 7.3 Hz, 1H), 4.12 (d, *J* = 6.4 Hz, 2H), 4.08 (d, *J* = 6.4 Hz, 2H), 2.31 (tt, *J* = 13.3, 6.6 Hz, 1H), 1.15 (dd, *J* = 11.7, 6.7 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 163.9, 163.6, 163.5, 163.4, 150.1, 149.7, 148.8, 143.1, 141.9, 141.8, 138.7, 138.4, 137.4, 137.3, 137.2, 134.6, 134.5, 133.9, 133.8, 133.2, 133.1, 132.9, 132.4, 130.8, 130.0, 129.1, 129.0, 128.8, 128.4, 128.3, 127.8, 127.7, 123.0, 122.4, 120.9, 120.8, 120.7, 118.7, 118.5, 116.7, 116.6, 114.4, 112.1, 111.7, 110.9, 110.7, 99.5, 98.5, 75.6, 75.2, 28.4, 28.3, 19.4. ³¹P NMR (243 MHz, CDCl₃) δ -4.90. HRMS (ESI) calculated for C₄₆H₄₅N₅O₄ [M + H]⁺: 762.3204, found 762.3197.




Compound **6**: Compound **5** (300 mg, 0.96 mmol, 1.0 equiv.), HPPh₂ (200 mg, 1.08 mmol, 1.1 equiv.) and Pd(PPh₃)₄ (100 mg, 10%) was added to a two-neck flask with condenser and the flask was filled with Ar. TEA (0.27 mL, 2.0 eq.) and THF was added though syringe respectively. The resulting mixture was stirred at 80 °C for 16 h. The mixture was poured into water and extracted with DCM and purified with silica gel column to obtain compound **6** as a yellow solid (320 mg, 75% yield). ¹H NMR (600 MHz, CDCl₃) δ 8.49 (d, *J* = 11.9 Hz, 1H), 8.03 (d, *J* = 7.2 Hz, 1H), 7.73 (d, *J* = 3.6 Hz, 1H), 7.60 (t, *J* = 7.8 Hz, 1H), 7.48 – 7.37 (m, 6H), 7.31 (t, *J* = 7.3 Hz, 4H), 3.95 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 165.5, 150.4, 150.3, 149.5, 149.2, 138.8, 134.6, 134.5, 133.2, 131.7, 131.5, 130.3, 130.2, 130.0, 129.5, 129.4, 127.3, 126.5, 124.3, 53.6, 53.4. ³¹P NMR (243 MHz, CDCl₃) δ -14.76. HRMS (ESI) calculated for C₂₃H₁₇N₂O₄P [M +

$\text{H}]^+$: 417.0999, found 417.0997.




Compound 7: Compound **6** (0.40 g, 0.96 mmol, 1.0 equiv.) was dissolved in a mixture of THF (8 mL), MeOH (2 mL) and H_2O (1 mL), NaOH (0.12 g, 2.88 mmol, 3.0 equiv.) was added and the mixture was stirred at 40 °C under Ar atmosphere. The progress of saponification was monitored by TLC. The solution was acidified with HCl (1 mol/L, aqueous), and then extracted with CH_2Cl_2 . The solvent was evaporated and the residue was dried under vacuum and used directly without further purification. (0.38 g, 98% yield). ^1H NMR (600 MHz, CDCl_3) δ 8.58 (d, J = 12.0 Hz, 1H), 8.18 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 3.0 Hz, 1H), 7.68 (t, J = 8.0 Hz, 2H), 7.47 (t, J = 7.4 Hz, 2H), 7.42 (t, J = 7.6 Hz, 4H), 7.32 (t, J = 7.9 Hz, 4H). ^{13}C NMR (150 MHz, CDCl_3) δ 164.9, 149.4, 148.8, 148.7, 141.9, 141.2, 139.6, 133.3, 132.1, 131.6, 130.6, 129.8, 129.4, 129.3, 128.7, 127.1, 127.0, 124.8, 108.1, 107.8, 106.5, 104.0. ^{31}P NMR (243 MHz, CDCl_3) δ -11.59. HRMS (ESI) calculated for $\text{C}_{22}\text{H}_{16}\text{N}_2\text{O}_4\text{P}$ [$\text{M} + \text{H}]^+$: 403.0842, found 403.0840.




Compound 8: Compound **6** (150 mg), ethyl acetate (25 mL) and Pd/C (10%) was added into a two-neck flask. The flask was filled with hydrogen and was stirred at room temperature for overnight under H_2 atmosphere. The reaction mixture was filtered and

the filtrate was concentrated to obtain compound **8** with quantitative yield. ^1H NMR (600 MHz, CDCl_3) δ 7.57 (d, $J = 4.2$ Hz, 1H), 7.51 (dd, $J = 8.3, 2.9$ Hz, 1H), 7.37 (dt, $J = 14.5, 7.4$ Hz, 6H), 7.31 (q, $J = 8.3, 7.8$ Hz, 5H), 6.91 (d, $J = 7.5$ Hz, 1H), 5.21 (br, 2H), 3.92 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 166.2, 148.0, 147.9, 145.9, 143.9, 134.6, 134.4, 132.7, 132.2, 132.1, 132.0, 131.8, 131.7, 130.2, 129.7, 129.1, 129.1, 125.3, 114.2, 114.0, 110.4, 52.8. ^{31}P NMR (243 MHz, CDCl_3) δ -12.85. HRMS (ESI) calculated for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_2\text{P} [\text{M} + \text{H}]^+$: 387.1257, found 387.1257.




Compound **9**: (1S)-(-)-camphanyl acid (125 mg, 0.63 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (0.11 mL, 2.0 equiv.) and DMF (cat.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution of compound **8** (220 mg, 0.57 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (0.33 mL, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 h. The solution was removed and the residue was applied to a flash column chromatography to get product as an off-white solid (290 mg, 90% yield). ^1H NMR (400 MHz, CDCl_3) δ 11.03 (s, 1H), 8.71 (d, $J = 7.7$ Hz, 1H), 7.95 (dd, $J = 8.5, 2.8$ Hz, 1H), 7.68 (d, $J = 3.8$ Hz, 1H), 7.54 (t, $J = 8.2$ Hz, 1H), 7.39 (p, $J = 6.7$ Hz, 6H), 7.29 (d, $J = 7.2$ Hz, 4H), 4.01 (s, 3H), 2.68 (ddd, $J = 14.1, 10.8, 4.2$ Hz, 1H), 2.12 (ddd, $J = 13.5, 9.3, 4.5$ Hz, 1H), 2.02 (tt, $J = 11.0, 4.5$ Hz, 1H), 1.79 (ddd, $J = 13.3, 9.3, 4.1$ Hz, 1H), 1.19 (d, $J = 5.0$ Hz, 6H), 1.05 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 177.7, 165.8, 165.7, 149.6, 149.4, 145.2, 137.3, 135.0, 134.5, 134.4, 133.9, 123.0, 129.6, 129.1,

125.3, 120.7, 120.6, 117.3, 92.9, 55.6, 54.5, 53.0, 30.4, 29.4, 16.9, 10.0. ^{31}P NMR (162 MHz, CDCl_3) δ -13.01. HRMS (ESI) calculated for $\text{C}_{33}\text{H}_{32}\text{N}_2\text{O}_5\text{P}$ [$\text{M} + \text{H}$] $^+$: 567.2043, found 567.2039.




Compound 10: Compound **6** (0.19 g, 0.34 mmol, 1.0 equiv.) was dissolved in dioxane (4 mL), NaOH (40 mg, 1.00 mmol, 3.0 equiv.) was added and the mixture was stirred at 40 °C under Ar atmosphere. The progress of saponification was monitored by TLC. The solution was acidified with HCl (1 mol/L, aqueous) and extracted with CH_2Cl_2 . The solvent was evaporated and the residue was dried under vacuum and was applied to a flash column chromatography to get product as an off-white solid (135 mg, 74% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.49 (s, 1H), 10.61 (s, 1H), 8.71 (d, J = 7.7 Hz, 1H), 7.88 (dd, J = 8.4, 2.8 Hz, 1H), 7.68 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 3.9 Hz, 1H), 7.46 (d, J = 10.2 Hz, 6H), 7.31 (t, J = 7.6 Hz, 4H), 4.03 (q, J = 7.1 Hz, 1H), 2.05 (q, J = 10.5, 9.3 Hz, 2H), 1.71 – 1.62 (m, 1H), 1.12 (s, 3H), 1.07 (s, 3H), 0.93 (s, 3H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 177.1, 165.6, 165.4, 148.7, 148.5, 146.2, 136.6, 134.5, 134.2, 134.0, 133.3, 130.0, 129.8, 129.4, 129.2, 124.9, 120.1, 120.0, 117.2, 92.0, 54.8, 53.8, 39.5, 30.1, 28.4, 16.4, 16.3, 9.5. ^{31}P NMR (162 MHz, $\text{DMSO}-d_6$) δ -13.90. HRMS (ESI) calculated for $\text{C}_{32}\text{H}_{30}\text{N}_2\text{O}_5\text{P}$ [$\text{M} + \text{H}$] $^+$: 553.1887, found 553.1886.




Compound L1: Compound **7** (30 mg, 0.073 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (16 μL , 2.5 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl

chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution of compound **4a** (50 mg, 0.066 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (40 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 18 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (50 mg, 66% yield). 1 H NMR (600 MHz, CDCl_3) δ 12.05 (s, 2H), 12.04 (s, 2H), 9.05 (d, J = 7.2 Hz, 1H), 8.92 (d, J = 12.2 Hz, 1H), 8.47 (dd, J = 8.9, 2.7 Hz, 1H), 8.02 (d, J = 10.0 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 4.2 Hz, 1H), 7.83 (s, 1H), 7.75 (t, J = 7.8 Hz, 1H), 7.57 (t, J = 6.0 Hz, 1H), 7.52 (d, J = 6.2 Hz, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.32 (d, J = 10.6 Hz, 5H), 7.25 – 7.15 (m, 12H), 7.08 (t, J = 6.6 Hz, 1H), 6.93 (s, 1H), 6.88 (t, J = 7.8 Hz, 1H), 6.77 (t, J = 7.8 Hz, 1H), 4.15 (t, J = 6.6 Hz, 2H), 3.86 (t, J = 6.6 Hz, 2H), 2.38 – 2.26 (m, 2H), 1.16 (t, J = 6.0 Hz, 12H). 13 C NMR (150 MHz, CDCl_3) δ 163.7, 163.3, 162.7, 162.6, 162.2, 151.6, 151.2, 150.9, 150.8, 150.6, 146.8, 145.6, 140.3, 139.6, 139.5, 139.1, 137.8, 136.7, 135.9, 134.7, 134.6, 133.9, 133.8, 133.2, 131.6, 131.4, 131.0, 130.9, 130.8, 130.7, 130.1, 129.7, 129.6, 129.4, 129.3, 129.0, 128.9, 128.6, 127.7, 126.0, 125.8, 125.1, 124.3, 122.5, 122.2, 121.2, 118.4, 118.3, 100.7, 99.5, 75.5, 75.2, 28.3, 19.4. 31 P NMR (243 MHz, CDCl_3) δ -4.30, -10.85. HRMS (ESI) calculated for $\text{C}_{68}\text{H}_{57}\text{N}_6\text{O}_8\text{P}_2$ [M + H] $^+$: 1147.3708, found 1147.3694.




Compound **L2**: Compound **7** (36 mg, 0.090 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (20 μ L, 2.5 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution

of compound **4a** (62 mg, 0.081 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (48 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 18 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (64 mg, 69% yield). 1 H NMR (600 MHz, CDCl₃) δ 12.06 (s, 1H), 11.92 (s, 1H), 9.48 (s, 1H), 8.97 (d, *J* = 7.4 Hz, 1H), 8.76 (d, *J* = 7.6 Hz, 1H), 8.52 (dd, *J* = 8.5, 3.3 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 1H), 7.96 (d, *J* = 9.7 Hz, 1H), 7.92 (s, 1H), 7.75-7.71 (m, 2H), 7.54 – 7.40 (m, 15H), 7.31 – 7.20 (m, 3H), 7.15 (t, *J* = 7.8 Hz, 3H), 7.04 (t, *J* = 7.0 Hz, 3H), 6.97 (t, *J* = 6.0 Hz, 1H), 6.92 (t, *J* = 6.6 Hz, 1H), 6.73 (d, *J* = 9.2 Hz, 1H), 4.22 (d, *J* = 6.1 Hz, 2H), 3.87 (d, *J* = 6.4 Hz, 2H), 2.38 (dt, *J* = 12.2, 6.6 Hz, 1H), 2.27 (dt, *J* = 13.0, 6.7 Hz, 1H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.15 (d, *J* = 6.7 Hz, 6H). 13 C NMR (150 MHz, CDCl₃) δ 164.1, 163.4, 162.5, 161.3, 160.8, 151.4, 150.9, 150.8, 148.5, 146.3, 139.3, 139.0, 138.7, 138.6, 137.6, 137.4, 137.3, 137.0, 136.9, 135.0, 134.9, 134.7, 134.4, 133.9, 133.8, 133.7, 133.6, 131.8, 131.7, 131.6, 130.2, 129.4, 129.2, 129.1, 128.6, 128.4, 128.3, 128.2, 128.1, 125.7, 125.4, 124.3, 124.1, 123.9, 122.7, 122.1, 119.3, 118.9, 118.8, 116.9, 116.4, 99.4, 97.9, 75.7, 75.5, 29.9, 28.4, 28.3, 19.5. 31 P NMR (243 MHz, CDCl₃) δ -4.11, -10.64. HRMS (ESI) calculated for C₆₈H₅₈N₇O₇P₂ [M + H]⁺: 1146.3867, found 1146.3860.




Compound **L3**: Compound **10** (47 mg, 0.087 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (16 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution of compound **4a** (60 mg, 0.079 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (45 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The

resulting mixture was stirred at room temperature for another 16 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (60 mg, 58% yield). ¹H NMR (600 MHz, CDCl₃) δ 12.32 (s, 1H), 12.24 (s, 1H), 10.07 (s, 1H), 8.92 (d, *J* = 7.5 Hz, 1H), 8.77 (d, *J* = 7.5 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.92 – 7.84 (m, 3H), 7.77 (d, *J* = 4.0 Hz, 1H), 7.68 – 7.63 (m, 2H), 7.55 (t, *J* = 8.0 Hz, 1H), 7.38 (dt, *J* = 18.6, 6.1 Hz, 3H), 7.31 (dd, *J* = 10.1, 6.1 Hz, 8H), 7.16 (ddt, *J* = 36.1, 14.9, 8.1 Hz, 13H), 7.10 – 7.06 (m, 1H), 6.92 (d, *J* = 8.1 Hz, 1H), 6.86 (d, *J* = 7.8 Hz, 1H), 6.77 (s, 1H), 4.19 (d, *J* = 7.5 Hz, 1H), 4.19 (d, *J* = 7.5 Hz, 1H), 3.81 (dq, *J* = 15.2, 8.4 Hz, 2H), 2.32 (ddt, *J* = 24.5, 13.2, 5.9 Hz, 3H), 1.79 (td, *J* = 12.7, 4.3 Hz, 1H), 1.62 (t, *J* = 8.8 Hz, 1H), 1.17 (dt, *J* = 5.8, 3.3 Hz, 12H), 0.84 (d, *J* = 5.2 Hz, 6H), 0.53 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 176.6, 165.1, 164.2, 163.8, 162.7, 162.5, 162.2, 151.0, 150.9, 150.5, 150.3, 148.9, 145.5, 139.3, 139.2, 138.9, 136.8, 136.0, 135.3, 134.8, 134.7, 134.6, 134.4, 134.0, 133.9, 133.8, 133.7, 133.6, 130.8, 130.7, 130.6, 130.4, 129.8, 129.7, 129.7, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.6, 128.5, 128.0, 127.6, 126.0, 125.8, 123.4, 122.5, 122.2, 121.4, 120.6, 120.5, 117.4, 116.8, 116.7, 116.1, 101.2, 99.2, 92.0, 75.4, 75.2, 55.0, 54.4, 29.9, 29.5, 29.0, 28.4, 22.9, 19.5, 19.4, 16.6, 16.5, 14.3, 9.9. ³¹P NMR (243 MHz, CDCl₃) δ -4.28, -10.67. HRMS (ESI) calculated for C₇₈H₇₁N₆O₉P₂ [M + H]⁺ : 1297.4752, found 1297.4734.




Compound **L4**: Compound **10** (60 mg, 0.109 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (20 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution of compound **4b** (75 mg, 0.098 mmol, 0.90 equiv.) in DCM was slowly added DIPEA

(60 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (67 mg, 53% yield). 1 H NMR (600 MHz, CDCl_3) δ 12.32 (s, 1H), 12.05 (s, 1H), 10.03 (s, 1H), 9.38 (s, 1H), 8.88 (d, J = 7.5 Hz, 1H), 8.59 (d, J = 7.3 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.94 – 7.90 (m, 2H), 7.87 (d, J = 7.7 Hz, 1H), 7.74 (s, 1H), 7.73 – 7.59 (m, 6H), 7.57 – 7.43 (m, 5H), 7.31 (dt, J = 16.9, 8.5 Hz, 7H), 7.24 (d, J = 7.2 Hz, 7H), 7.12 (ddd, J = 28.7, 14.7, 7.4 Hz, 6H), 6.97 (t, J = 7.8 Hz, 1H), 6.93 (t, J = 7.5 Hz, 2H), 6.87 (s, 1H), 6.82 (t, J = 6.6 Hz, 1H), 6.66 (d, J = 9.2 Hz, 1H), 4.28 – 4.23 (m, 1H), 4.18 – 4.13 (m, 1H), 3.85 (dq, J = 15.3, 8.4 Hz, 2H), 2.43 – 2.20 (m, 4H), 2.17-2.10 (m, 1H), 1.81-1.77 (m, 1H), 1.67 – 1.58 (m, 2H), 1.24 – 1.15 (m, 12H), 0.83 (d, J = 8.2 Hz, 6H), 0.51 (s, 3H). 13 C NMR (150 MHz, CDCl_3) δ 176.6, 165.0, 164.2, 163.5, 163.3, 161.6, 160.1, 150.6, 148.6, 148.5, 138.9, 138.2, 137.6, 137.5, 137.3, 137.2, 137.0, 136.9, 135.8, 135.7, 135.5, 134.7, 134.5, 134.0, 133.9, 133.8, 133.7, 130.2, 129.7, 129.4, 129.2, 129.1, 129.0, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.7, 124.2, 124.0, 123.3, 122.6, 122.0, 121.1, 119.6, 118.0, 117.0, 116.8, 116.6, 99.3, 92.1, 75.6, 75.4, 55.1, 54.4, 32.1, 30.4, 29.9, 29.6, 29.0, 28.4, 19.4, 16.6, 16.5, 9.9. 31 P NMR (243 MHz, CDCl_3) δ -4.17, -10.58. HRMS (ESI) calculated for $\text{C}_{78}\text{H}_{72}\text{N}_7\text{O}_8\text{P}_2$ [M + H] $^+$: 1296.4912, found 1296.4895.



Compound L5: Compound **10** (15 mg, 0.026 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (5 μ L 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution

of compound **4c** (18 mg, 0.024 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (14 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The resulting mixture was stirred at room temperature for another 16 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (12 mg, 39% yield). 1 H NMR (600 MHz, CDCl₃) δ 12.48 (s, 1H), 12.19 (s, 1H), 10.46 (d, *J* = 8.1 Hz, 1H), 10.01 (s, 1H), 8.95 (d, *J* = 7.3 Hz, 1H), 8.52 (d, *J* = 7.5 Hz, 1H), 8.07 – 7.83 (m, 8H), 7.70 – 7.58 (m, 7H), 7.53 (t, *J* = 7.9 Hz, 1H), 7.36 (br, 7H), 7.17 (t, *J* = 8.0 Hz, 1H), 7.06 (t, *J* = 12.2 Hz, 2H), 6.89 (t, *J* = 7.1 Hz, 5H), 6.81 (t, *J* = 6.5 Hz, 4H), 6.67 (s, 1H), 6.47 (s, 1H), 5.90 (s, 2H), 4.16 (br, 1H), 3.95 (br, 1H), 3.85 – 3.73 (m, 2H), 2.39 – 2.17 (m, 5H), 2.01 (br, 1H), 1.81 (br, 1H), 1.63 (br, 1H), 1.14 (d, *J* = 10.9 Hz, 12H), 0.86 (dd, *J* = 31.8, 14.7 Hz, 6H), 0.50 (s, 3H). 13 C NMR (150 MHz, CDCl₃) δ 176.6, 165.2, 164.5, 163.7, 163.1, 161.8, 159.8, 139.4, 139.3, 139.0, 138.1, 135.9, 134.6, 134.5, 133.9, 133.8, 133.6, 133.1, 133.0, 132.3, 131.1, 130.8, 130.7, 130.3, 129.7, 129.6, 129.5, 129.4, 129.1, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.5, 127.4, 124.7, 123.6, 122.8, 121.9, 121.1, 121.0, 120.9, 117.2, 116.9, 116.6, 116.4, 101.8, 99.3, 98.0, 92.1, 75.2, 55.0, 54.4, 32.1, 29.9, 29.6, 29.5, 29.0, 28.4, 27.4, 22.9, 19.6, 19.4, 16.6, 16.5, 14.3, 9.9. 31 P NMR (243 MHz, CDCl₃) δ -10.88, -19.33. HRMS (ESI) calculated for C₇₈H₇₂N₇O₈P₂ [M + H]⁺ : 1296.4912, found 1296.4900.



Compound L6: Compound **10** (64 mg, 0.12 mmol, 1.0 equiv.) was dissolved in DCM under Ar and to this solution oxalyl chloride (22 μ L, 2.0 equiv.) was added. The mixture was stirred for 2 hrs at room temperature and then the solvents and surplus oxalyl chloride were removed under reduced pressure to obtain the corresponding acyl chloride, which was dried for another 2 hrs and resolved in dry DCM. To the solution of compound **4d** (80 mg, 0.10 mmol, 0.90 equiv.) in DCM was slowly added DIPEA (63 μ L, 3.00 equiv.), the acid chloride solution through a dry syringe in order. The

resulting mixture was stirred at room temperature for another 16 hrs. The solution was removed and the residue was applied to a flash column chromatography to get product as a yellow solid (30 mg, 25% yield). ^1H NMR (600 MHz, CDCl_3) δ 12.30 (s, 1H), 12.07 (s, 1H), 10.09 (s, 1H), 9.56 (s, 1H), 8.88 (s, 1H), 8.52 (s, 1H), 8.06 – 7.90 (m, 4H), 7.77 – 7.60 (m, 6H), 7.58 – 7.34 (m, 20H), 7.24 – 7.13 (m, 2H), 7.02 (d, J = 8.4 Hz, 2H), 6.88 (s, 1H), 6.80 (d, J = 7.2 Hz, 2H), 4.28 – 4.19 (m, 1H), 4.10 (s, 1H), 3.94 – 3.84 (m, 2H), 2.83 (s, 1H), 2.43 – 2.14 (m, 6H), 2.02 (s, 1H), 1.83 (d, J = 13.0 Hz, 1H), 1.24 – 1.10 (m, 18H), 0.55 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 176.8, 165.0, 164.1, 163.5, 163.4, 161.5, 159.8, 151.0, 150.7, 150.6, 148.6, 148.2, 138.6, 138.1, 137.9, 137.8, 137.4, 137.2, 135.8, 135.7, 135.6, 134.5, 134.4, 134.2, 134.1, 134.0, 133.4, 131.9, 131.8, 131.1, 130.8, 130.6, 130.3, 129.9, 129.6, 129.2, 129.0, 128.9, 128.8, 128.7, 128.6, 127.8, 127.7, 123.3, 122.5, 122.0, 121.1, 121.0, 118.6, 118.5, 117.7, 117.1, 116.6, 116.6, 99.3, 98.2, 92.2, 75.5, 55.1, 30.4, 29.9, 29.0, 28.4, 19.5, 19.4, 16.7, 16.5, 9.9. ^{31}P NMR (243 MHz, CDCl_3) δ -5.31, -11.11. HRMS (ESI) calculated for $\text{C}_{78}\text{H}_{72}\text{N}_7\text{O}_8\text{P}_2$ $[\text{M} + \text{H}]^+$: 1296.4912, found 1296.4903.

3. ^1H NMR, ^{31}P NMR, MS and CD spectra for L[Rh] complexes

The procedure for the formation of L[Rh] complexes: One equivalent Rh(Cod)₂BF₄ was added to a solution of the bisphosphine ligand and the ^1H NMR, ^{31}P NMR, MS and CD spectra were conducted in a few minutes.




Fig. S1 ^1H NMR spectra of **L1** and the corresponding **L1[Rh]** in CDCl_3 at 298 K.




Fig. S2 ^{31}P NMR spectra of **L1** and the corresponding **L1[Rh]** ($J = 43.74 \text{ Hz}, 216.3 \text{ Hz}$) in CDCl_3 at 298 K.




Fig. S3 ¹H NMR spectra of **L2** and the corresponding **L2[Rh]** in CDCl₃ at 298 K.




Fig. S4 ³¹P NMR spectra of **L2** and the corresponding **L2[Rh]** ($J_{P,P}=29.16$ Hz, $J_{P,Rh}=140.9, 143.4$ Hz) in CDCl₃ at 298 K.




Fig. S5 ¹H NMR spectra of **L3** and the corresponding **L3[Rh]** in CDCl₃ at 298 K.




Fig. S6 ^{31}P NMR spectra of **L3** and the corresponding **L3[Rh]** ($J = 26.7$ Hz, 145.8 Hz) in CDCl_3 at 298 K.




Fig. S7 ^1H NMR spectra of **L4** and the corresponding **L4[Rh]** in CDCl_3 at 298 K.




Fig. S8 ^{31}P NMR spectra of **L4** and the corresponding **L4[Rh]** ($J_{\text{P-P}}=48.6$ Hz, $J_{\text{P-Rh}}=172.5$, 143.4 Hz) in CDCl_3 at 298 K.




Fig. S9 ¹H NMR spectra of **L5** and the corresponding **L5[Rh]** in CDCl₃ at 298 K.




Fig. S10 ³¹P NMR spectra of **L5** and the corresponding **L5[Rh]** in CDCl₃ at 298 K.




Fig. S11 ¹H NMR spectra of **L6** and the corresponding **L6[Rh]** in CDCl₃ at 298 K.




Fig. S12 Part of the variable temperature 600 MHz ^1H NMR spectra of **L4** at (a) 298 K, (b) 273 K, (c) 253 K, (d) 233 K, (e) 213 K and (f) 193 K in CD_2Cl_2 .




Fig. S13 ESI-Ms spectra of **L1**[Rh] calculated for $\text{C}_{76}\text{H}_{69}\text{N}_6\text{O}_8\text{P}_2\text{Rh}^+$: 1357.3629, found 1357.3618.




Fig. S14 ESI-MS spectra of **L2**[Rh] calculated for $C_{76}H_{69}N_7O_7P_2Rh^+$: 1356.3789, found 1356.3778.




Fig. S15 ESI-MS spectra of **L3**[Rh] calculated for $C_{86}H_{82}N_6O_9P_2Rh^+$: 1507.4674, found 1507.4672.




Fig. S16 ESI-MS spectra of **L4**[Rh] calculated for $\text{C}_{86}\text{H}_{83}\text{N}_7\text{O}_8\text{P}_2\text{Rh}^+$: 1506.4828, found 1506.4832.




Fig. S17 ESI-MS spectra of **L5**[Rh] calculated for $\text{C}_{86}\text{H}_{83}\text{N}_7\text{O}_8\text{P}_2\text{Rh}^+$: 1506.4828, found 1506.4832.




Fig. 18 CD spectra of **L3** and **L3[Rh]** in DCM at 298 K.




Fig. 19 CD spectra of **L4** and **L4[Rh]** in DCM at 298 K.




Fig. 20 CD spectra of **L5** and **L5[Rh]** in DCM at 298 K.





Fig. 21 CD spectra of **L6** and **L6[Rh]** in DCM at 298 K.

4. General procedure for the hydrogenation reaction

5.1 Synthesis of compound **1a-1g**

Compound **1a-1g** and their hydrogenation products are known compounds and were prepared according to the literature (*Angew. Chem. Int. Ed.*, 2015, **54**, 4334-4337). The ¹H NMR spectra are consistent with the literature



Compound **1a**: White solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.46 (d, *J* = 4.0 Hz, 2H), 7.39-7.35 (m, 3H), 3.85 (s, 3H), 2.14 (s, 3H).

Compound **1b**: Off-white solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.46 – 7.30 (m, 3H), 7.24 (br, 1H), 6.99 – 6.92 (m, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 2.07 (s, 3H).

Compound **1c**: White solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.38 – 7.27 (m, 2H), 7.11 – 6.84 (m, 4H), 3.85 (s, 3H), 3.80 (s, 3H), 2.14 (s, 3H).

Compound **1d**: White solid. ¹H NMR (600 MHz, CDCl₃-*d*) δ 7.42 (d, *J* = 22.5 Hz, 3H), 6.92 (d, *J* = 37.8 Hz, 3H), 3.84 (s, 6H), 2.16 (s, 3H).

Compound **1e**: White solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.44 (br, 1H), 7.31 (d, *J* = 10.7 Hz, 4H), 7.03 (br, 1H), 3.86 (s, 3H), 2.15 (s, 3H).

Compound **1f**: White solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.45 (br, 2H), 7.40 (br, 1H), 7.05 (t, *J* = 8.5 Hz, 2H), 6.98 (br, 1H), 3.86 (s, 3H), 2.16 (s, 3H).

Compound **1g**: White solid. ¹H NMR (400 MHz, CDCl₃-*d*) δ 7.43 – 7.32 (m, 3H), 7.18 (d, *J* = 7.4 Hz, 2H), 6.92 (s, 1H), 3.84 (s, 3H), 2.36 (s, 3H), 2.15 (s, 3H).

5.2 Characterization Data of reduced products

Compound **1a–H**: ¹H NMR (600 MHz, CDCl₃-*d*) δ 7.29 (t, *J* = 7.3 Hz, 2H), 7.24 (d, *J* = 7.4 Hz, 1H), 7.09 (d, *J* = 7.2 Hz, 2H), 5.90 (s, 1H), 4.89 (q, *J* = 5.8 Hz, 1H), 3.73 (s, 3H), 3.17 – 3.07 (m, 2H), 1.99 (s, 3H).

Compound **1b–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.24 (td, J = 8.2, 1.6 Hz, 1H), 7.09 – 7.05 (m, 1H), 6.92 – 6.85 (m, 2H), 6.22 (s, 1H), 4.74 (q, J = 6.7 Hz, 1H), 3.84 (s, 3H), 3.71 (s, 3H), 3.10 (s, 2H), 1.93 (s, 3H).

Compound **1c–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.20 (t, J = 7.9 Hz, 1H), 6.79 (d, J = 6.9 Hz, 1H), 6.67 (d, J = 7.5 Hz, 1H), 6.63 (s, 1H), 5.92 (s, 1H), 4.92 – 4.84 (m, 1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.09 (qd, J = 13.8, 5.7 Hz, 2H), 1.99 (s, 3H).

Compound **1d–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.00 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 5.88 (s, 1H), 4.84 (q, J = 5.7 Hz, 1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.06 (qd, J = 14.0, 5.6 Hz, 2H), 1.99 (s, 3H).

Compound **1e–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.22 (d, J = 5.8 Hz, 2H), 7.08 (s, 1H), 6.98 (d, J = 5.8 Hz, 1H), 5.96 (s, 1H), 4.87 (q, J = 5.9 Hz, 1H), 3.74 (s, 3H), 3.10 (ddd, J = 43.4, 13.9, 5.7 Hz, 2H), 2.00 (s, 3H).

Compound **1f–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.08 – 7.02 (m, 2H), 6.97 (t, J = 8.5 Hz, 2H), 5.92 (s, 1H), 4.86 (q, J = 6.0 Hz, 1H), 3.72 (s, 3H), 3.16 – 3.03 (m, 2H), 1.99 (s, 3H).


Compound **1g–H**: ^1H NMR (600 MHz, CDCl_3 -*d*) δ 7.09 (d, J = 7.7 Hz, 2H), 6.97 (d, J = 7.8 Hz, 2H), 5.93 – 5.82 (m, 1H), 4.91 – 4.80 (m, 1H), 3.73 (s, 3H), 3.08 (qd, J = 13.9, 5.7 Hz, 2H), 2.31 (s, 3H), 1.98 (s, 3H).

5.3 General procedure for the hydrogenation reaction

To a 5-mL vial containing a magnetic stirring bar was added the substrate (0.2 mmol) and the Rh(I)-complex in a solution under an argon atmosphere. The vial was purged three times with hydrogen and finally pressurized to 7 or 10 atm. The reaction mixture was stirred at room temperature for several hours. The residual hydrogen gas was released in a hood, and the conversion were determined by ^1H NMR analysis of the crude mixture. The reaction mixture was concentrated in vacuum, and the residue was purified by flash chromatography on silica gel with petroleum ether and ethyl acetate (10/1) as the eluent to afford the corresponding product as an off-white solid. The *ee* of the products were determined by GC using a Varian Chirasil-L-Val column CP7495 (25 m *0.25 mm). The ^1H NMR and GC spectra determining the conversions and *ee* values were shown blow. When 4% mol L2[Rh] or L1[Rh] was used as the catalyst, the

conversions of the hydrogenation for **1a-1g** were over 98% in the solvents CDCl_3 , toluene and THF and the ^1H NMR spectra were shown only once.

Table S1 Optimization for Hydrogenation of α -dehydroamino acid esters based on **L2**.




Entry	Substrate (R)	Conv. (%) ^a	Conv. (%) ^b	Conv. (%) ^c	Conv. (%) ^d	Conv. (%) ^e
1	1a (H)	30	94	>98	>98	>98
2	1b (2-OMe)	20	85	>98	>98	>98
3	1c (3-OMe)	15	84	>98	>98	>98
4	1d (4-OMe)	80	80	>98	>98	>98
5	1e (3-Cl)	80	72	>98	>98	>98
6	1f (4-F)	60	>98	>98	>98	>98
7	1g (2-Me)	65	>98	>98	>98	>98

Conditions: ^a 1 atm of H_2 , **L2**/Rh(Cod_2BF_4)/substrate=2/2/100, CDCl_3 ;

^b 10 atm of H_2 , **L2**/Rh(Cod_2BF_4)/substrate=2/2/100, CDCl_3 ;

7 atm of H_2 , **L2**/Rh(Cod_2BF_4)/substrate=4/4/100, 12 h, the solvent are ^c CDCl_3 , ^dTHF and ^etoluene; respectively; the conversions were determined by ^1H NMR spectra.

Table S2 Optimization for Hydrogenation of α -dehydroamino acid esters based on **L1**.



Entry	Substrate (R)	Conv. (%) ^a	Conv. (%) ^b	Conv. (%) ^c
1	1a (H)	>98	>98	>98
2	1b (2-OMe)	>98	>98	>98
3	1c (3-OMe)	>98	>98	>98
4	1d (4-OMe)	>98	>98	>98
5	1e (3-Cl)	>98	>98	>98
6	1f (4-F)	>98	>98	>98
7	1g (2-Me)	>98	>98	>98

Conditions: 7 atm of H_2 , **L1**/Rh(Cod_2BF_4)/substrate=4/4/100, 12 h, and the conversions were determined by ^1H NMR spectra, the solvents are ^a CDCl_3 , ^bTHF and ^ctoluene respectively.




Fig. S22 The ¹H NMR spectrum of the hydrogenation of **1a** when 2% L2[Rh] and 1 atm of H₂ were used. The conversion of this reaction is 30%.




Fig. S23 The ¹H NMR spectrum of the hydrogenation of **1b** when 2% L2[Rh] and 1 atm of H₂ were used. The conversion of this reaction is 20%.




Fig. S24 The ^1H NMR spectrum of the hydrogenation of **1c** when 2% L2[Rh] and 1 atm of H_2 were used. The conversion of this reaction is 15%.




Fig. S25 The ^1H NMR spectrum of the hydrogenation of **1d** when 2% L2[Rh] and 1 atm of H_2 were used. The conversion of this reaction is 80%.




Fig. S26 The ^1H NMR spectrum of the hydrogenation of **1e** when 2% L2[Rh] and 1 atm of H_2 were used. The conversion of this reaction is 80%.




Fig. S27 The ^1H NMR spectrum of the hydrogenation of **1f** when 2% L2[Rh] and 1 atm of H_2 were used. The conversion of this reaction is 60%.




Fig. S28 The ^1H NMR spectrum of the hydrogenation of **1g** when 2% L2[Rh] and 1 atm of H_2 were used. The conversion of this reaction is 65%.




Fig. S29 The ^1H NMR spectrum of the hydrogenation of **1a** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 94%.




Fig. S30 The ^1H NMR spectrum of the hydrogenation of **1b** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 85%.




Fig. S31 The ^1H NMR spectrum of the hydrogenation of **1c** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 84%.




Fig. S32 The ^1H NMR spectrum of the hydrogenation of **1d** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 80%.




Fig. S33 The ^1H NMR spectrum of the hydrogenation of **1e** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 72%.




Figure S34. The ^1H NMR spectrum of the hydrogenation of **1f** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 98%.




Fig. S35 The ^1H NMR spectrum of the hydrogenation of **1g** when 2% L2[Rh] and 10 atm of H_2 were used. The conversion of this reaction is 98%.




Fig. S36 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S37 The ^1H NMR spectrum of the hydrogenation of **1b** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S38 The ^1H NMR spectrum of the hydrogenation of **1c** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S39 The ^1H NMR spectrum of the hydrogenation of **1d** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S40 The ^1H NMR spectrum of the hydrogenation of **1e** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S41 The ^1H NMR spectrum of the hydrogenation of **1f** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S42 The ^1H NMR spectrum of the hydrogenation of **1g** when 4% L2[Rh] or L1[Rh] was used. The conversion of these reactions are 98%.




Fig. S43 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L3[Rh] was used in CDCl_3 , THF or toluene. The conversions of these reactions are 98%.




Fig. S44 The GC spectrum of the racemic hydrogenation product 1a-H.




Fig. S45 The GC spectrum of the hydrogenation product 1a-H when L3[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S46 The GC spectrum of the hydrogenation product **1a-H** when L3[Rh] was used as the catalyst and THF as the solvent.




Fig. S47 The GC spectrum of the hydrogenation product **1a-H** when L3[Rh] was used as the catalyst and toluene as the solvent.




Fig. S48 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L4[Rh] was used in THF. The conversions of these reactions are 76%.




Fig. S49 The GC spectrum of the hydrogenation product **1a-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S50 The GC spectrum of the hydrogenation product **1a-H** when L4[Rh] was used as the catalyst and THF as the solvent.




Fig. S51 The GC spectrum of the hydrogenation product **1a-H** when L4[Rh] was used as the catalyst and toluene as the solvent.




Fig. S52 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L5[Rh] was used in CDCl_3 . The conversions of these reactions are 10%.




Fig. S53 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L5[Rh] was used in THF. The conversions of these reactions are 6%.




Fig. S54 The ^1H NMR spectrum of the hydrogenation of **1a** when 4% L5[Rh] was used in toluene. The conversions of these reactions are 5%.




Fig. S55 The GC spectrum of the hydrogenation product **1a-H** when L6[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S56 The GC spectrum of the hydrogenation product **1a-H** when L6[Rh] was used as the catalyst and THF as the solvent.




Fig. S57 The GC spectrum of the hydrogenation product **1a-H** when L6[Rh] was used as the catalyst and toluene as the solvent.




Fig. S58 The GC spectrum of the racemic hydrogenation product **1b-H**.




Fig. S59 The GC spectrum of the hydrogenation product **1b-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S60 The GC spectrum of the racemic hydrogenation product **1c-H**.




Fig. S61 The GC spectrum of the hydrogenation product **1c-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S62 The GC spectrum of the racemic hydrogenation product **1d-H**.




Fig. S63 The GC spectrum of the hydrogenation product **1d-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S64 The GC spectrum of the racemic hydrogenation product **1e-H**.




Fig. S65 The GC spectrum of the hydrogenation product **1e-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S66 The GC spectrum of the racemic hydrogenation product **1f-H**.




Fig. S67 The GC spectrum of the hydrogenation product **1f-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.




Fig. S68 The GC spectrum of the racemic hydrogenation product **1g-H**.




Fig. S69 The GC spectrum of the hydrogenation product **1g-H** when L4[Rh] was used as the catalyst and CDCl_3 as the solvent.

5. Crystal data


Table S3. Crystal data and structure refinement for **L1** and **L2**.

	L1	L2
Empirical formula	C68H56N6O8P2	C68H57N7O7P2·3CHCl3
Formula weight	1147.12	1504.25
Temperature (K)	100.01(10)	101
Crystal System	triclinic	monoclinic
Space group	P-1	P2 ₁ /c
<i>a</i> (Å)	13.6368(19)	19.2392(7)
<i>b</i> (Å)	14.139(2)	11.0026(5)
<i>c</i> (Å)	15.614(2)	33.5952(16)
α (deg)	104.059(13)	90
β (deg)	92.816(11)	101.948(4)
γ (deg)	92.523(13)	90
Volume (Å ³)	2911.9(8)	6957.4(5)
<i>Z</i>	2	4
ρ_{calcg} (cm ⁻³)	1.309	1.436
μ (mm ⁻¹)	1.194	4.236
Crystal size (mm ³)	0.3 × 0.25 × 0.1	0.2 × 0.15 × 0.05
<i>F</i> (000)	1202.0	3096.0
2 Θ range for data	7.572 to 149.228	7.84 to 147.11
Index ranges	-14 ≤ <i>h</i> ≤ 16, -17 ≤ <i>k</i> ≤ 11, -19 ≤ <i>l</i> ≤ 19	-21 ≤ <i>h</i> ≤ 23, -9 ≤ <i>k</i> ≤ 13, -39 ≤ <i>l</i> ≤ 41
Reflections collected	19760	25470
Independent reflections	11269 [Rint = 0.1968, Rsigma = 0.2452]	13445 [Rint = 0.0946, Rsigma = 0.1093]
Data/restraints/parameters	11269/6/765	13445/66/888
Goodness-of-fit on <i>F</i> ²	1.074	0.999
Final R indexes [<i>I</i> >= 2 σ (<i>I</i>)]	R1 = 0.2092, wR2 = 0.4601	R1 = 0.1092, wR2 = 0.2783
Final R indexes [all data]	R1 = 0.3367, wR2 = 0.5528	R1 = 0.1436, wR2 = 0.2979
Largest diff. peak/hole (e·Å ⁻³)	1.42/-0.71	0.97/-0.87
CCDC#	1939544	1939549


6. ^1H NMR, ^{31}P NMR and ^{13}C NMR spectra of new compounds

Compound L1


^1H NMR (600 MHz, 298 K, CDCl_3)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




¹³C NMR (150 MHz, 298 K, CDCl₃)




Compound L2


¹H NMR (600 MHz, 298 K, CDCl₃)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




^{13}C NMR (150 MHz, 298 K, CDCl_3)



Compound L3

¹H NMR (600 MHz, 298 K, CDCl₃)




³¹P NMR (243 MHz, 298 K, CDCl₃)


L33-0530

single pulse decoupled gated NOE

-4.28
-10.67




¹³C NMR (150 MHz, 298 K, CDCl₃)




Compound L4


¹H NMR (600 MHz, 298 K, CDCl₃)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




^{13}C NMR (150 MHz, 298 K, CDCl_3)



Compound **L5**

¹H NMR (600 MHz, 298 K, CDCl₃)





³¹P NMR (243 MHz, 298 K, CDCl₃)

L37-0607

single pulse decoupled gated NOE


-10.88
-19.33





Compound L6

¹H NMR (600 MHz, 298 K, CDCl₃)




^{31}P NMR (243 MHz, 298 K, CDCl_3)


L41-0607

single pulse decoupled gated NOE

-5.31
-11.11




^{13}C NMR (150 MHz, 298 K, CDCl_3)




Compound 6


^1H NMR (600 MHz, 298 K, CDCl_3)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




¹³C NMR (150 MHz, 298 K, CDCl₃)




Compound 7


¹H NMR (600 MHz, 298 K, CDCl₃)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




^{13}C NMR (150 MHz, 298 K, CDCl_3)




Compound 8


^1H NMR (600 MHz, 298 K, CDCl_3)



^{31}P NMR (243 MHz, 298 K, CDCl_3)




¹³C NMR (150 MHz, 298 K, CDCl₃)



Compound 9

¹H NMR (400 MHz, 298 K, CDCl₃)



^{31}P NMR (162 MHz, 298 K, CDCl_3)


L17

— -13.015




^{13}C NMR (150 MHz, 298 K, CDCl_3)

-177.70
165.82
165.70
149.60
149.45
145.16
137.34
134.97
134.54
134.40
133.89
129.95
129.62
129.14
125.30
120.73
120.59
117.28
92.87
77.20
55.64
30.38
29.35
54.49
53.05
-16.87
-9.99




Compound **10**


^1H NMR (400 MHz, 298 K, DMSO- d_6)



^{31}P NMR (162 MHz, 298 K, DMSO- d_6)




¹³C NMR (150 MHz, 298 K, DMSO-*d*₆)



Compound 4a

¹H NMR (600 MHz, 298 K, CDCl₃)




^{31}P NMR (243 MHz, 298 K, CDCl_3)

L32-0529

single pulse decoupled gated NOE


-4.42



Compound 4b

¹H NMR (600 MHz, 298 K, CDCl₃)


L20-0507
single_pulse




³¹P NMR (243 MHz, 298 K, CDCl₃)

L20-0507

single pulse decoupled gated NOE




¹³C NMR (150 MHz, 298 K, CDCl₃)



Compound 4c

¹H NMR (600 MHz, 298 K, CDCl₃)




^{31}P NMR (243 MHz, 298 K, CDCl_3)

L36-0606

single pulse decoupled gated NOE

-19.32




^{31}P NMR (243 MHz, 298 K, CDCl_3)



L40-0606

single pulse decoupled gated NOE

-4.90



^{13}C NMR (150 MHz, 298 K, CDCl_3)



7. References

1. G. H. Ouyang, Y. M. He, Y. Li, J. F. Xiang and Q. H. Fan, *Angew. Chem. Int. Ed.*, 2015, **54**, 4334-4337.
2. R. Gramage-Doria, J. Hessels, S. H. Leenders, O. Troppner, M. Durr, I. Ivanovic-Burmazovic and J. N. Reek, *Angew. Chem. Int. Ed.*, 2014, **53**, 13380-13384.
3. D. Gelman, L. Jiang and S. L. Buchwald, *Org. Lett.*, 2003, **5**, 2315-2318.
4. M. Xue, J. Li, J. Peng, Y. Bai, G. Zhang, W. Xiao and G. Lai, *Appl. Organomet. Chem.*, 2014, **28**, 120-126.
5. J. Buratto, C. Colombo, M. Stupfel, S. J. Dawson, C. Dolain, B. Langlois d'Estaintot, L. Fischer, T. Granier, M. Laguerre, B. Gallois and I. Huc, *Angew. Chem. Int. Ed.*, 2014, **53**, 883-887.
6. X. Li, N. Markandeya, G. Jonusauskas, N. D. McClenaghan, V. Maurizot, S. A. Denisov and I. Huc, *J. Am. Chem. Soc.*, 2016, **138**, 13568-13578.